The study highlights significant racial disparities in cancer research, citing that between 2008 and 2018, only 7.8% of clinical trials documented the four major races (including white, Asian, Black, and Hispanic populations) in the United States.
Data from two large cancer centers in the United States have shown that the COVID-19 pandemic caused substantial disruption to clinical trials for cancer treatment and care.